Related Experiment Video
Updated: Jan 10, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.9K
Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment
Arthur Karaulic1, Clémence Fournier1, Gilles Pagès1
1University Côte d'Azur, Institute for Research on Cancer and Ageing of Nice (IRCAN, UMR CNRS 7284/U INSERM 1081), 06100 Nice, France.
Cancers
|November 27, 2025
Summary
This study reveals that medulloblastoma, a pediatric cancer, shows varied expression of drug targets, influencing patient survival. Investigating approved tyrosine kinase inhibitors and other drugs could offer new treatment avenues for specific medulloblastoma subgroups.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Pediatric tumors like medulloblastoma are understudied for targeted therapies.
- Tyrosine kinase inhibitors (TKI), therapeutic antibodies, and apoptosis inducers have transformed cancer treatment.
- Understanding target expression in specific medulloblastoma genetic subgroups is key for drug repositioning.
Purpose of the Study:
- To assess the expression of 73 potential drug targets in medulloblastoma.
- To evaluate the correlation between target expression and patient survival.
- To identify potential repositioning opportunities for FDA-approved drugs in medulloblastoma.
Main Methods:
- Analyzed RNA-sequencing data from 763 patients (R2 Genomics platform) and 828 patients (TCGA).
- Assessed expression of targets for TKIs, immune checkpoint inhibitors (ICI), and apoptosis inducers.
- Examined treatments targeting mutated genes relevant to tumorigenesis or therapy resistance.
Main Results:
- Overexpression of certain targets correlated with altered overall survival in medulloblastoma patients.
- Specific immune checkpoint inhibitors showed differential effects across subgroups.
- Venetoclax, a drug for hematological tumors, showed potential efficacy in medulloblastoma.
Conclusions:
- Medulloblastoma exhibits subtype-specific expression of drug targets, impacting survival.
- Approved TKIs, ICIs, and pro-apoptotic drugs warrant clinical investigation in medulloblastoma.
- Targeted therapies tailored to genetic subgroups may improve outcomes.
Related Concept Videos
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K